SHBG, sex hormone binding globulin, 6462

N. diseases: 368; N. variants: 20
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.100 Biomarker group BEFREE Stage 2 hypertension (SBP/DBP ≥ 140/90 mmHg) showed significant associations with cardiovascular disease and all-cause mortality, while elevated blood pressure (SBP 120-129 mmHg and DBP < 80 mmHg) showed null associations. 31288541 2020
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.100 Biomarker group BEFREE Epidemiological studies reported an inconsistent association between stage 1 hypertension (SBP 130-139 mmHg or DBP 80-89 mmHg) defined by the 2017 American College of Cardiology/American Heart Association hypertension guidelines and cardiovascular disease (CVD) events. 31790053 2020
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.100 Biomarker group BEFREE The association between lower SBP and lesser risk of CVD may instead suggest a beneficial effect of lower SBP. 31188164 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.100 Biomarker group BEFREE Risk of total CVDs, MI, and stroke was increased with low-range prehypertension (low-range: SBP 120-129 mmHg and/or DBP 80-84 mmHg) versus normal BP - RR 1.42 (95% CI 1.29-1.55), 1.43 (1.10-1.86), and 1.52 (1.27-1.81), respectively - and risk of total CVDs, CHD, MI, and stroke was increased with high-range prehypertension (high-range: SBP 130-139 mmHg and/or DBP 85-89 mmHg) - RR 1.81 (95% CI 1.56-2.10), 1.65 (1.13-2.39), 1.99 (1.59-2.50), and 1.99 (1.68-2.36), respectively. 31335511 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.100 Biomarker group BEFREE Testosterone and its binding protein sex hormone-binding globulin have been associated with cardiovascular disease and dysglycaemia. 30567457 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.100 Biomarker group BEFREE Eligible participants (N = 50, mean age 74 ± 7 years, 34% men, 26% with history of cardiovascular disease) had higher SBP during the anesthesiologic than the cardiological evaluation (157 ± 23 vs. 144 ± 18 mmHg, P < 0.001), and the former levels were almost identical to those clinically measured just before surgery. 30950973 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.100 Biomarker group BEFREE Newly defined stage 1 hypertension and elevated BP were associated with increased risk of incident CVD, whereas long-term changes of SBP and DBP had effects of varying degree on CVD incidence. 31116159 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.100 Biomarker group BEFREE A positive dose-response relationship of daily walking duration with quartiles of SHBG was seen after adjustment for age, sex, history of cardiovascular diseases, diabetes, smoking, γ-glutamyl transferase, and C-reactive protein (p for trend = .010). 30676188 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.100 Biomarker group BEFREE We analyzed OH measurements from the Action to Control Cardiovascular Risk in Diabetes BP trial, which evaluated two blood pressure (BP) goals (systolic BP [SBP] < 120 mm Hg vs. SBP < 140 mm Hg) and incident CVD among adults with diabetes and hypertension. 30715100 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.100 GeneticVariation group BEFREE In the dipping group, only night-day ratio of SBP was significantly associated with CVD, with an odds ratio (OR) of 1.09 (95% confidence interval (CI) of 1.02-1.34). 30899285 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.100 Biomarker group BEFREE If identified, such changes may have important clinical relevance, particularly, as low sex hormone binding globulin (SHBG) and follicle stimulating hormone (FSH) are known to promote metabolic and cardiovascular disease in women. 30339729 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.100 GeneticVariation group BEFREE Median HbA<sub>1c</sub> overall was 55 mmol/mol (7.2%), median SBP was 132 mmHg, median total cholesterol was 4.1 mmol/l and mean BMI was 32 kg/m<sup>2</sup><sub>.</sub> Overall two-thirds (65% of men, 68% of women) have two or more of the following CVD risk factor thresholds: HbA<sub>1c</sub> ≥ 53 mmol/mol (7%), SBP > 130 mmHg or DBP > 80 mmHg, total cholesterol ≥ 5 mmol/l or BMI ≥ 30 kg/m<sup>2</sup> , or were currently smoking. 30246473 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.100 Biomarker group BEFREE The certainty of the evidence was moderate for SBP and low for CVD incidence and ranged from very low to moderate for the secondary outcomes. 30764511 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.100 Biomarker group BEFREE Neither SHBG nor TT was significantly associated with all-age CVD mortality [hazard ratio (HR), 0.69; 95% CI, 0.29 to 1.63; P = 0.40; and HR, 0.60; 95% CI, 0.28 to 1.26; P = 0.18, respectively]. 31390027 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.100 Biomarker group BEFREE We used cross-sectional data from 2913 men aged 76.7 ± 3.2 years with morning blood samples assayed for T, DHT, E2 (mass spectrometry), and sex hormone-binding globulin (SHBG, immunoassay), to correlate sex hormones with LTL measured using PCR and expressed as T/S ratio in multivariable linear regression models adjusted for age, cardiometabolic risk factors and cardiovascular disease history. 30561819 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.100 GeneticVariation group BEFREE Our findings support a SBP treatment target of 140 mmHg and suspect no risk reduction attenuation on CVD for lower SBP targets (<120 or <130 mmHg) for most patients with uncomplicated T2DM. 29592967 2018
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.100 GeneticVariation group BEFREE Total estradiol (E<sub>2</sub>), total testosterone (TT), androstenedione (AD), dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), sex hormone-binding globulin (SHBG) and NT-proBNP were assessed in 4112 postmenopausal women free of cardiovascular diseases from the prospective population-based Rotterdam Study. 29551255 2018
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.100 Biomarker group BEFREE Investigate relations of mass spectrometry-assessed estrone (E1), E2, and T and SHBG and subclinical CVD in women. 29788255 2018
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.100 Biomarker group BEFREE Adjusted cubic spline analysis showed significant nonlinear but different association between SBP and CVD mortality among diabetes mellitus (U-shaped) and NON-DM (J-shaped). 28800042 2018
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.100 Biomarker group BEFREE Background Both sex hormone-binding globulin and central obesity have been found to be associated with metabolic and cardiovascular diseases. 29770358 2018
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.100 Biomarker group BEFREE Linear, logistic, and Cox regression models assessed the association of top quartiles (P75) of serum testosterone, free androgen index (FAI), dehydroepiandrosterone, and androstenedione and sex hormone-binding globulin with coronary artery calcium, carotid intima-media thickness (IMT), pulse wave velocity, peripheral artery disease, and incidence of coronary heart disease (CHD), stroke, and CVD. 29408955 2018
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.100 Biomarker group BEFREE To explore the association between systolic and diastolic blood pressure (SBP and DBP respectively) and pulse pressure (PP) with cardiovascular disease (CVD) and mortality events among Iranian patients with prevalent CKD. 30111315 2018
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.100 AlteredExpression group BEFREE AGHD = adult growth hormone deficiency; ASCVD = atherosclerotic cardiovascular disease; AUROC = area under the receiver operating characteristic curve; BMI = body mass index; CVAI = Chinese visceral adiposity index; CVD = cardiovascular disease; DBP = diastolic blood pressure; GH = growth hormone; GHRT = GH replacement therapy; HDL-C = high-density lipoprotein cholesterol; IGF-1 = insulin like factor-1; IGFBP-3 = insulin like factor binding protein-3; IR = insulin resistance; LAP = lipid accumulation product; MS = metabolic syndrome; SBP = systolic blood pressure; TC = total cholesterol; TG = triglycerides; VAI = visceral adiposity index; WC = waist circumference; WHR = waist-to-hip ratio. 29144802 2018
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.100 Biomarker group BEFREE Furthermore, CR decreased blood pressure (SBP -8 ± 3 mmHg, P = 0.005; DBP -6 ± 2 mmHg, P < 0.001), total cholesterol (-13.6 ± 5.3 mg/dl, P = 0.001), and LDL-cholesterol (-12.9 ± 4.4 mg/dl, P = 0.005), and the 10-yr risk of CVD-disease was reduced by 30%. 29351490 2018
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.100 Biomarker group BEFREE Additionally, participants with CVD had significantly higher central SBP and AIx@75 compared with those without CVD. 29049227 2017